Given the shared pathophysiology between AF and HFpEF, SGLT2 inhibitors may reduce AF susceptibility not only through anti-inflammatory and metabolic effects but also by lowering left atrial pressure and wall stress via improved diastolic function and volume unloading [209,210]. Here, SLC5A2 is linked to atrial fibrillation.